60,769 Shares in Boston Scientific Corporation $BSX Bought by Indivisible Partners

Indivisible Partners acquired a new stake in Boston Scientific Corporation (NYSE:BSX) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 60,769 shares of the medical equipment provider’s stock, valued at approximately $5,794,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its holdings in Boston Scientific by 1.0% in the fourth quarter. Vanguard Group Inc. now owns 139,685,997 shares of the medical equipment provider’s stock valued at $13,319,060,000 after buying an additional 1,436,550 shares in the last quarter. Invesco Ltd. increased its holdings in Boston Scientific by 0.7% in the third quarter. Invesco Ltd. now owns 16,963,344 shares of the medical equipment provider’s stock valued at $1,656,131,000 after buying an additional 111,826 shares in the last quarter. Northern Trust Corp increased its holdings in Boston Scientific by 0.9% in the third quarter. Northern Trust Corp now owns 14,402,636 shares of the medical equipment provider’s stock valued at $1,406,129,000 after buying an additional 128,188 shares in the last quarter. Amundi increased its holdings in Boston Scientific by 17.5% in the third quarter. Amundi now owns 11,981,584 shares of the medical equipment provider’s stock valued at $1,158,619,000 after buying an additional 1,781,830 shares in the last quarter. Finally, Legal & General Group Plc increased its holdings in Boston Scientific by 4.6% in the third quarter. Legal & General Group Plc now owns 10,457,175 shares of the medical equipment provider’s stock valued at $1,020,934,000 after buying an additional 463,889 shares in the last quarter. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have weighed in on the stock. Mizuho cut their price objective on shares of Boston Scientific from $115.00 to $90.00 and set an “outperform” rating for the company in a report on Monday, April 13th. Evercore cut their target price on shares of Boston Scientific from $112.00 to $96.00 and set an “outperform” rating for the company in a research note on Thursday, February 5th. Argus raised shares of Boston Scientific to a “strong-buy” rating in a research note on Thursday, February 26th. Sanford C. Bernstein reissued an “outperform” rating and set a $112.00 target price on shares of Boston Scientific in a research note on Friday, February 6th. Finally, Truist Financial cut their target price on shares of Boston Scientific from $90.00 to $85.00 and set a “buy” rating for the company in a research note on Thursday, April 23rd. One analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $93.91.

Boston Scientific Stock Down 1.5%

Shares of NYSE BSX opened at $55.98 on Wednesday. Boston Scientific Corporation has a 12-month low of $55.88 and a 12-month high of $109.50. The stock has a market cap of $83.20 billion, a PE ratio of 23.42, a P/E/G ratio of 1.04 and a beta of 0.62. The company has a current ratio of 1.90, a quick ratio of 1.08 and a debt-to-equity ratio of 0.42. The company has a 50-day moving average of $66.69 and a 200 day moving average of $84.28.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.79 by $0.01. Boston Scientific had a net margin of 17.29% and a return on equity of 19.17%. The company had revenue of $5.20 billion during the quarter, compared to analysts’ expectations of $5.19 billion. During the same quarter in the prior year, the company earned $0.75 EPS. Boston Scientific’s revenue was up 11.6% compared to the same quarter last year. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. As a group, sell-side analysts predict that Boston Scientific Corporation will post 3.38 EPS for the current fiscal year.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.